$heff's $tation of $tocks & $olid DD

[$heff]

Alert...bought shares of CYCC at $2.38 in the Established Portfolio. They are presenting 6 abstracts at the AACR meeting that starts on Monday (Apr 17th-21st). These are solid forward-looking events to move this higher. This could move over $3.00 next week with the small float and O/S imo. DD posts to follow. $heff


6 abstracts at AACR for next week presentations.


>>> Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

Translational Studies Highlight Unique Mechanism of Action and New Potential Clinical Applications for Sapacitabine and Seliciclib

April 1, 2010

BERKELEY HEIGHTS, N.J., April 1, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News) (Nasdaq:CYCCP - News) today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

The abstracts can be accessed through the AACR website, http://www.aacr.org/. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

Sapacitabine:

"Understanding the pathways involved in the repair of CNDAC induced DNA damage"
Date/Time: Tuesday, Apr 20, 2010, 9:00 - 12:00 EDT
Abstract Number: 3502

Seliciclib and Second Generation CDK Inhibitors:

"Cyclin E amplification, a novel mechanism of resistance to trastuzumab
in HER2 amplified breast cancer"
Date/Time: Sunday, Apr 18, 2010, 14:25 -- 14:40 EDT
Abstract Number: 22


"Therapeutic potential of CDK inhibitors in MLL leukemias"
Date/Time: Tuesday, Apr 20, 2010, 14:00 -- 17:00 EDT
Abstract Number: 3886

"A novel derivative of the CDK inhibitor roscovitine that induces apoptosis in CLL and overcomes
stromal cell-mediated protection"
Date/Time: Tuesday, Apr 20, 2010, 14:00 -- 17:00 EDT
Abstract Number: 4431


CYC116:

"Tumor cell resistance mechanisms to aurora kinase inhibitors"
Date/Time: Sunday, Apr 18, 2010, 14:00 -- 17:00 EDT
Abstract Number: 633


Plk1 Inhibitors:

"Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1)
selective small molecule inhibitors"
Date/Time: Tuesday, Apr 20, 2010, 14:00 - 17:00 EDT
Abstract Number: 4435 <<<